- Drugs
- Wednesday, 15 Jul 2020
AstraZeneca ties up with IQVIA to speed up studies of COVID-19 vaccine candidate
Life sciences company IQVIA Holdings Inc said on Tuesday it would collaborate with AstraZeneca Plc to speed up clinical studies of the British drugmaker’s potential COVID-19 vaccine in the United States.
The collaboration is part of the U.S. government’s Operation Warp Speed to accelerate the development of COVID-19 vaccines and treatments.
AstraZeneca is among the drugmakers farthest along in the race to develop a safe and effective vaccine for COVID-19, the respiratory disease caused by the new coronavirus. The British drugmaker has received U.S. funding of more than $1 billion to secure access to dosages.
The agreement includes an expansive study of trial participants and will use IQVIA’s virtual trial solutions that would make parts of the study remote.
Clinical trial service providers like IQVIA have seen a boost in demand for their offerings in virtual care - an area that has been slow to catch on - as the pandemic forces people to self-isolate and stay at home.
Related Industry Updates
CRO industry faces consolidation
Sep 04, 2019
Aurora Cannabis and UFC Launch Clinical Research on Use of Hemp-Derived CBD Products by MMA Athletes
Sep 20, 2019
Chronic Cough Market Key Factors and Emerging Opportunities with Current Trends Analysis 2027
Jul 13, 2020
Eybna and CannaSoul, Top Cannabis R&D Firms, Join Forces to Prove a Proprietary Terpene Formulation for Treating Viral Infections via Modulation of Cytokine Storm
Apr 22, 2020
Novartis scraps sale of assets including COVID-19 hopeful to Indis's Aurobindo Pharma
Apr 02, 2020
North America Radiopharmaceutical Theragnostic Market is expected to reach US$ 1,529.88 million by 2028
Mar 13, 2023
Pharmaceutics International Selected as A Winner of Two GH&P Awards
May 04, 2020
Follow us on
